Locations:
SearchLearn about featured Cancer clinical trials currently enrolling, or search our Cancer clinical trials database for all open and accruing studies
Leukemia, Acute Myeloid (AML)
A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute Myeloid Leukemia (AML)
CASE 2914 | #15-851
View full trial information
NSCLC (Non-small cell lung cancer)
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
ZNCA 1515 | #15-1161
View full trial information
Renal
A Phase II study of the efficacy and safety of Axitinib given on an individualized schedule for metastatic renal cell cancer after treatment with PD-1 or PD-l1 inhibitor
CASE 7815 | #15-1386
View full trial information
Pancreas
A Randomized Phase II Study of Perioperative mFolfirinox Versus Gemcitabine/Nab-Paclitaxel as Therapy for resectable Pancreatic Adenocarcinoma
SWOG 1505 | #15-1472
View full trial information
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients